Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-04-01
|
| Series: | Alzheimer’s Research & Therapy |
| Online Access: | https://doi.org/10.1186/s13195-023-01230-9 |
| _version_ | 1797841157630197760 |
|---|---|
| author | Bruno Dubois Jesús López‑Arrieta Stanley Lipschitz Triantafyllos Doskas Luiza Spiru Svitlana Moroz Olena Venger Patrick Vermersch Alain Moussy Colin D. Mansfield Olivier Hermine Magda Tsolaki for the AB09004 Study Group Investigators |
| author_facet | Bruno Dubois Jesús López‑Arrieta Stanley Lipschitz Triantafyllos Doskas Luiza Spiru Svitlana Moroz Olena Venger Patrick Vermersch Alain Moussy Colin D. Mansfield Olivier Hermine Magda Tsolaki for the AB09004 Study Group Investigators |
| author_sort | Bruno Dubois |
| collection | DOAJ |
| first_indexed | 2024-04-09T16:26:31Z |
| format | Article |
| id | doaj.art-8a299e1b5fb94a1cbdfb460cdf520c8f |
| institution | Directory Open Access Journal |
| issn | 1758-9193 |
| language | English |
| last_indexed | 2024-04-09T16:26:31Z |
| publishDate | 2023-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Alzheimer’s Research & Therapy |
| spelling | doaj.art-8a299e1b5fb94a1cbdfb460cdf520c8f2023-04-23T11:11:12ZengBMCAlzheimer’s Research & Therapy1758-91932023-04-011511110.1186/s13195-023-01230-9Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trialBruno Dubois0Jesús López‑Arrieta1Stanley Lipschitz2Triantafyllos Doskas3Luiza Spiru4Svitlana Moroz5Olena Venger6Patrick Vermersch7Alain Moussy8Colin D. Mansfield9Olivier Hermine10Magda Tsolaki11for the AB09004 Study Group InvestigatorsAlzheimer Research Center IM2A, Salpêtrière Hospital, AP-HP, Sorbonne UniversityCantoblanco Memory Clinic, Geriatric Department, Hospital CantoblancoThe Dr Stanley Lipschitz Clinic Inc, RosebankNeurological Department, Athens Naval HospitalCarol Davila University of Medicine and Pharmacy, The Excellence Clinic of Geriatrics, Gerontology and Old Age PsychiatryPsychosomatic Center Based On Psychoneurology Department of Communal Enterprise ‘Dnipropetrovsk Regional Clinical Hospital Named After I.I. Mechnikov’, Dnipropetrovsk Regional CouncilDepartment Psychiatry, Narcology and Medical Psychology I, Horbachevsky Ternopil National Medical UniversityUniv. Lille, UMR Inserm U1172, CHU Lille, FHU PreciseAB ScienceAB ScienceAB ScienceFirst Department of Neurology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessalonikihttps://doi.org/10.1186/s13195-023-01230-9 |
| spellingShingle | Bruno Dubois Jesús López‑Arrieta Stanley Lipschitz Triantafyllos Doskas Luiza Spiru Svitlana Moroz Olena Venger Patrick Vermersch Alain Moussy Colin D. Mansfield Olivier Hermine Magda Tsolaki for the AB09004 Study Group Investigators Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial Alzheimer’s Research & Therapy |
| title | Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial |
| title_full | Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial |
| title_fullStr | Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial |
| title_full_unstemmed | Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial |
| title_short | Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial |
| title_sort | correction masitinib for mild to moderate alzheimer s disease results from a randomized placebo controlled phase 3 clinical trial |
| url | https://doi.org/10.1186/s13195-023-01230-9 |
| work_keys_str_mv | AT brunodubois correctionmasitinibformildtomoderatealzheimersdiseaseresultsfromarandomizedplacebocontrolledphase3clinicaltrial AT jesuslopezarrieta correctionmasitinibformildtomoderatealzheimersdiseaseresultsfromarandomizedplacebocontrolledphase3clinicaltrial AT stanleylipschitz correctionmasitinibformildtomoderatealzheimersdiseaseresultsfromarandomizedplacebocontrolledphase3clinicaltrial AT triantafyllosdoskas correctionmasitinibformildtomoderatealzheimersdiseaseresultsfromarandomizedplacebocontrolledphase3clinicaltrial AT luizaspiru correctionmasitinibformildtomoderatealzheimersdiseaseresultsfromarandomizedplacebocontrolledphase3clinicaltrial AT svitlanamoroz correctionmasitinibformildtomoderatealzheimersdiseaseresultsfromarandomizedplacebocontrolledphase3clinicaltrial AT olenavenger correctionmasitinibformildtomoderatealzheimersdiseaseresultsfromarandomizedplacebocontrolledphase3clinicaltrial AT patrickvermersch correctionmasitinibformildtomoderatealzheimersdiseaseresultsfromarandomizedplacebocontrolledphase3clinicaltrial AT alainmoussy correctionmasitinibformildtomoderatealzheimersdiseaseresultsfromarandomizedplacebocontrolledphase3clinicaltrial AT colindmansfield correctionmasitinibformildtomoderatealzheimersdiseaseresultsfromarandomizedplacebocontrolledphase3clinicaltrial AT olivierhermine correctionmasitinibformildtomoderatealzheimersdiseaseresultsfromarandomizedplacebocontrolledphase3clinicaltrial AT magdatsolaki correctionmasitinibformildtomoderatealzheimersdiseaseresultsfromarandomizedplacebocontrolledphase3clinicaltrial AT fortheab09004studygroupinvestigators correctionmasitinibformildtomoderatealzheimersdiseaseresultsfromarandomizedplacebocontrolledphase3clinicaltrial |